论文部分内容阅读
目的:观察参麦注射液联合紫杉醇和卡铂治疗中晚期卵巢癌的临床疗效。方法:将46例患者随机分为2组,治疗组24例采用紫杉醇和卡铂化疗,联合参麦注射液治疗。对照组22例单纯采用紫杉醇和卡铂化疗。结果:近期疗效总有效率治疗组为62.50%,对照组为54.55%,2组比较,差异无显著性意义(P>0.05);治疗后外周血白细胞治疗组为(5.25±1.67)×109/L,对照组为(4.29±1.47)×109/L,2组比较,差异有显著性意义(P<0.05);2组治疗后T细胞亚群除CD8外,CD3、CD4及CD4/CD8比较,差异均有显著性意义(P<0.05);治疗后Karnofsky评分改善率治疗组(54.17%)高于对照组(27.27%),差异有显著性意义(P<0.05)。结论:参麦注射液联合紫杉醇和卡铂治疗中晚期卵巢癌可以减轻化疗的不良反应,改善机体免疫功能和提高患者生活质量。
Objective: To observe the clinical efficacy of Shenmai injection combined with paclitaxel and carboplatin in the treatment of advanced ovarian cancer. Methods: 46 patients were randomly divided into two groups, the treatment group of 24 patients with paclitaxel and carboplatin chemotherapy, combined with shenmai injection. Twenty-two patients in the control group were treated with paclitaxel and carboplatin alone. Results: The total effective rate in the short term was 62.50% in the treatment group and 54.55% in the control group. There was no significant difference between the two groups (P> 0.05). After treatment, the peripheral blood leukocyte count was (5.25 ± 1.67) × 109 / L, and the control group was (4.29 ± 1.47) × 109 / L. There was significant difference between the two groups (P <0.05). Compared with CD8, CD3, CD4 and CD4 / CD8 (P <0.05). After treatment, the improvement rate of Karnofsky score in treatment group (54.17%) was higher than that in control group (27.27%), the difference was significant (P <0.05). Conclusion: Shenmai injection combined with paclitaxel and carboplatin in the treatment of advanced ovarian cancer can reduce adverse reactions of chemotherapy, improve immune function and improve patients’ quality of life.